ATG-041

**ATG-041** is an investigational **small-molecule dual inhibitor of AXL and MerTK** being developed by **Antengene** for oncology. Company materials describe it as an **Axl-Mer inhibitor** intended to provide both **tumor-specific killing** and **modulation of the immune microenvironment**, consistent with inhibition of the TAM family receptor tyrosine kinases AXL and MerTK, which are implicated in tumor cell survival, invasion, drug resistance, and immunosuppressive macrophage biology. Publicly available Antengene pipeline disclosures placed ATG-041 in **preclinical, IND-track early development** for **solid tumors and hematologic malignancies**, while third-party pipeline databases later list the program as **discontinued/terminated** before clinical advancement.